secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dianthus Therapeutics, Inc. /DE/ (DNTH)
CIK:        0001690585
Form:       8-K/A
Filed at:   2023-09-21T23:59:59+00:00
Accession:  0001193125-23-238850
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dianthus files OpCo historical financials; pro forma cash runway into Q2 2026
-----------------------------------------------------------------------------

- OpCo net losses: $18.2M (H1 2023), $28.5M (FY2022), $13.1M (FY2021).
- Pro forma combined cash sufficient to fund operations into Q2 2026 per risk factors.
- Board classified: Class I (2025 AGM), Class II (2026 AGM), Class III (2024 AGM).
- Shares outstanding as of 9/21/2023: 14,813,295.
- Material weakness identified in internal control over financial reporting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1690585/000119312523238850/0001193125-23-238850-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1690585/000119312523238850/d520077d8ka.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-238850

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer